Replies to post #805277 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Henny Penny,



You are posting verifiably false statements over & over. We’re supposed to believe that MHRA told you this?:

“The MHRA has done its job in evaluating the application and has advised NWBO that the application cannot be approved unless they conduct a proper trial and provide patient-level data.”

Fact ✅️: MHRA did not tell you anything or publish any statement like the one you posted.

Fact ✅️: You will find the real “hoodwinker” here:

Fact ✅️: The UK government has responded to inquiries several times to indicate that their review has not yet concluded. They confirmed procedural status as recently as Nov 2025 & Dec 2025:





Fact ✅: MHRA has granted SEVERAL APPROVALS, including their approval of the MIA (a prerequisite of the MAA) & their ongoing support of the DCVax-L Specials Program.

Mar 2023, NWBO & Advent MIA Approval


Aug 2022, NWBO PIP Approval


Dec 2021, NWBO & Advent GMP License Approval



Regarding the P3, enrollment completed years before 2020, but patients continued to be treated & followed under the trial protocol as trial participants after enrollment closed. The P3 trial concluded in 2020, & data lock happened in Q4 of 2020…

COMBOS with checkpoint inhibitors & other agents are much more recent & have reached P2 for both DCVax-L & the Roswell aDC1 platform.

⭐️Combo is King!⭐️

NICE UK 🇬🇧 DCVax-L

Fact-Checking

[williamssc]

Whoa, you sound panicky. Two years on a new complex biologic is not unusually long.